Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 6/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 2/20 | 0.30 |
| ▸ | BRAF | P15056 | 2/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505567 | 0.87 | FAAH (0.36) | FAAHIDH1GSK3BTP53BP1 | |
| SCHEMBL436179 | 0.85 | GRIA2 (0.35) | FAAHOPRM1OPRD1OPRK1 | |
| SCHEMBL346196 | 0.80 | GSK3B (0.46) | FAAHGSK3B | |
| SCHEMBL435694 | 0.80 | GHSR (0.35) | OPRM1OPRD1OPRK1 | |
| SCHEMBL435890 | 0.78 | FAAH (0.37) | FAAHGSK3BRAF1BRAF | |
| SCHEMBL434259 | 0.74 | F10 (0.39) | FAAHTP53BP1 | |
| SCHEMBL10197873 | 0.72 | KARS1 (0.45) | FAAHGSK3BDYRK1A | |
| SCHEMBL345716 | 0.72 | KHK (0.40) | — | |
| SCHEMBL346726 | 0.72 | GSK3B (0.41) | FAAHGSK3BDYRK1AWNT1 | |
| SCHEMBL345400 | 0.71 | GSK3B (0.43) | FAAHGSK3BDYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |